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Monosomal karyotype confers a poor prognosis in patients withacute myeloid leukemia. Here, we determined the impact of thetype of remission-induction chemotherapy and the impact of hav-
ing a donor in younger acute myeloid leukemia patients with a monosomal
karyotype included in two phase III trials. In the first trial patients were ran-
domized to receive either daunorubicin, mitoxantrone, or idarubicin in
addition to standard-dose cytarabine and etoposide for induction
chemotherapy. In the second trial patients were randomized to standard-
dose cytarabine or high-dose cytarabine induction, both with daunorubicin
and etoposide. In both trials, patients who achieved a complete remission
with or without complete hematologic recovery underwent allogeneic
hematopoietic stem cell transplantation if they had a donor; otherwise,
they underwent autologous transplantation. In comparison to patients with
intermediate-risk cytogenetics without a monosomal karyotype (n=1,584)
and with adverse cytogenetics without a monosomal karyotype (n=218),
patients with a monosomal karyotype (n=188) were more likely not to
achieve a complete remission with or without count recovery [odds
ratio=2.85, 95% confidence interval (95%, CI): 2.10-3.88] and had shorter
overall survival [hazard ratio, (HR)=2.44, 95% CI: 2.08-2.88]. There was no
impact of the type of anthracycline or of the dose of cytarabine on out-
comes in patients with a monosomal karyotype. Among monosomal
karyo type patients who achieved a complete remission with or without
count recovery, HLA-identical related donor availability was associated
with longer survival from complete remission with or without count recov-
ery (HR=0.59, 95% CI: 0.37-0.95). ClinicalTrials.gov identifiers: AML-10:
NCT00002549; AML-12: NCT00004128.
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ABSTRACT
Introduction
The prognosis of young adult patients with intermediate/high-risk acute myel-
ogenous leukemia (AML) remains unsatisfactory. With current remission induc-
tion chemotherapy, 15-40% of such patients fail to achieve a complete remission
(CR), and only 30-50% of them remain alive for more than 5 years.1-4
Approximately 55% of AML patients have at least one chromosomal abnormali-
ty that can be detected by conventional cytogenetics.5 In
younger AML patients, the karyotype of leukemic cells
has remained one of the main prognostic factors.5,6
Specifically, patients can be classified into a favorable,
intermediate or adverse group.5,6 This classification not
only provides information on prognosis, but also influ-
ences the choice of post-remission treatment.5,7 In 2008,
Breems et al. identified a group of cytogenetic abnormal-
ities, termed monosomal karyo type (MK), which was
associated with a particularly poor prognosis.8 MK is
defined as the presence of two or more autosomal mono-
somies, or a single monosomy in the presence of struc-
tural abnormalities.8,9
The aim of this study was to determine the impact of
the type of remission-induction chemotherapy and allo-
geneic hematopoietic stem cell transplantation (HSCT) in
younger AML patients with a MK, using the data from the
European Organization for Research and Treatment on
Cancer/Gruppo Italiano Malattie Ematologiche dell'Adulto
(EORTC/GIMEMA) AML-10 and AML-12 phase III multi-
center trials. 
Methods
Study design
In the EORTC Leukemia Group/GIMEMA AML-10 trial,2
patients 15-60 years old were randomized to receive either
daunorubicin (50 mg/m2), mitoxantrone (12 mg/m2), or idarubicin
(10 mg/m2) on days 1, 3 and 5 in addition to standard-dose cytara-
bine (25 mg/m2 bolus followed by 100 mg/m2 given as a continu-
ous infusion daily for 10 days) and etoposide (100 mg/m2 on days
1-5) for induction chemotherapy. 
In the EORTC Leukemia Group/GIMEMA AML-12 trial,1
patients 15-60 years old were randomized between standard-dose
cytarabine induction: daunorubicin (50 mg/m2 per day on days 1,
3, and 5) plus etoposide (50 mg/m2 per day on days 1-5) plus 10
days of cytarabine (100 mg/m2 per day as a continuous intra-
venous infusion) and high-dose cytarabine induction: daunoru-
bicin (50 mg/m2 on days 1, 3, and 5) plus etoposide (50 mg/m2 per
day on days 1-5) plus cytarabine (3,000 mg/m2 every 12 h as a 3 h
intravenous infusion on days 1, 3, 5, and 7). 
In both trials, a second cycle of induction was administered to
patients who achieved a partial response. Patients who achieved a
CR or a CR with incomplete blood count recovery (CRi) after one
or two courses of induction chemotherapy received consolidation
chemotherapy with the same anthracycline as in the induction
course plus intermediate-dose cytarabine (500 mg/m2 every 12 h
as a 2 h intravenous infusion on days 1-6). Younger patients (<46
years in AML-10 and <50-60 years in AML-12) were then sched-
uled to undergo allogeneic HSCT in first CR/CRi if they had an
HLA-identical family donor (in both trials) or if they had an unre-
lated donor and needed two induction courses to achieve a
CR/CRi or had chromosome abnormalities involving 3q, 5, 7,
11q23, t(6;9), t(9;22) or complex abnormalities (in the AML-12
trial). Patients without a donor were scheduled to undergo autol-
ogous HSCT in first CR/CRi.
Ethics approval and consent to participation
This is a retrospective analysis limited to data from patients
included in phase III multicenter prospective trials (either the
EORTC/GIMEMA AML-10 or the EORTC/GIMEMA AML-12).
Both prospective phase III trials were approved by the internal
review boards of EORTC and GIMEMA and the ethical commit-
tee of each participating institution, and were conducted in accor-
dance with the Declaration of Helsinki. All patients signed the
respective informed consent form.
Cytogenetic assessment
Cytogenetic examinations were performed at diagnosis.
Cytogenetic data were centrally reviewed.2 For the current analy-
sis, cytogenetics were centrally re-reviewed, described according
to International System for Cytogenetic Nomenclature (ISCN)10
and classified using the refined UK Medical Research Council
(MRC) classification.6 MK was defined as the presence of two or
more autosomal monosomies or a single monosomy in the pres-
ence of structural abnormalities, as introduced by Breems et al.8
Statistical analyses
The duration of overall survival (OS) was calculated from the
date of randomization until death. The Kaplan-Meier method was
used to estimate the OS rates.11 Confidence intervals for the 5-year
OS rates were obtained using the normal approximation of the
distribution of log[-log(survival)] and the Greenwood variance for-
mula.12 The confidence interval of the median OS from CR/CRi
was estimated based on the Brookmeyer and Crowley method.13
Log-rank tests and Cox models were used to compare OS
between groups.14 Logistic regression was used to assess associa-
tions with CR/CRi achievement after induction. The analysis was
stratified (in the case of survival analysis) or adjusted (in the case
of logistic regression) by protocol when it included data from two
trials. Multivariate Cox and logistic regression models were per-
formed to assess the associations of MK and adverse MRC risk
group with outcomes, adjusting for known prognostic factors. A
Fisher exact test was used to investigate the association between
two categorical variables. All reported P-values are two-sided. SAS
9.4 software (SAS Institute Inc. Cary, NC, USA) was used for the
statistical analyses.
Results
Patients
In the AML-10 trial, 2,157 patients were randomized to
receive daunorubicin, mitoxantrone or idarubicin. The
current analyses were performed in a subgroup of 911
patients for whom cytogenetic data were available and
who did not have t(8;21), inv(16) or t(15;17); 696 of them
were classified in the MRC intermediate cytogenetic risk
group and 215 in the adverse group. Out of the 911
patients, 93 had a MK (5 with intermediate-risk cytoge-
netics and 88 with adverse risk) (Table 1, Figure 1). In the
AML-12 trial, 1,942 patients were randomized between
high-dose cytarabine or standard-dose cytarabine. The
current analyses were performed in a subgroup of 1,079
patients for whom cytogenetic data were available and
who did not have t(8;21), inv(16) or t(15;17); 896 of them
were classified in the MRC intermediate cytogenetic risk
group and 182 in the adverse-risk group (information was
missing for 1 patient). Out of these 1,079 patients, 95 had
a MK (4 with intermediate-risk cytogenetics and 91 with
adverse-risk) (Table 1, Figure 1). The patients’ median fol-
low up was 10.8 years in the whole population, 16.6 years
among those in the AML-10 study and 9.9 years among
AML-12 patients.
Monosomal karyotype is an independent poor prognostic
factor in young acute myeloid leukemia patients
The impact of MK on AML outcomes was assessed by
comparing outcomes of patients without MK and without
MK in EORTC/GIMEMA AML-10&12
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adverse-risk cytogenetics (NotAdvMK–, n=1,584), those
without MK but with adverse-risk cytogenetics (AdvMK–,
n=218) and those with a MK (MK+, n=188).  
Achievement of complete response with or without
blood count recovery
Patients with AdvMK– [odds ratio (OR)=1.80, 95% con-
fidence interval (95% CI): 1.33-2.42] or MK+ (OR=3.09,
95% CI: 2.26-4.22) had a higher probability of not reach-
ing a CR/CRi after induction compared to NotAdvMK–
patients (Table 2). CR/CRi was achieved in 76%, 63% and
50% of NotAdvMK–, AdvMK– and MK+ patients, respec-
tively. Comparing MK+ to MK– patients (NotAdvMK– or
AdvMK–), the odds of not achieving a CR/CRi were
almost three times higher (OR=2.85, 95% CI: 2.10-3.88)
for MK+ patients. The probability of not achieving a
CR/CRi was also significantly higher in MK+ than in
AdvMK– patients (OR=1.72, 95% CI: 1.15-2.57).
In a multivariate logistic regression model including age,
WHO Performance Status, and white blood cell count,
AdvMK– (OR 1.91, 95% CI: 1.41-2.59) and MK+ (OR 3.34,
95% CI: 2.42-4.59) were associated with higher probabil-
ities of not achieving a CR/CRi compared to NotAdvMK–
(Table 2). 
Overall survival 
The 5-year OS rates were 39.1%, 24.1% and 7.2% in
the NotAdvMK–, AdvMK– and MK+ patients, respectively
(Figure 2A). The estimated hazard ratios comparing
AdvMK– and MK+ patients to NotAdvMK– patients were
1.48 and 2.58, respectively (Table 3). Comparing MK+ to
MK– (NotAdvMK– or AdvMK–) and AdvMK– patients, the
estimates of the unadjusted hazard ratio were 2.44 (95%
CI: 2.08-2.88) and 1.74 (95% CI: 1.41-2.15), respectively.
In a multivariate Cox model, in comparison to
NotAdvMK– patients, those with AdvMK– (HR 1.51, 95%
CI: 1.28-1.77) or MK+ (HR 2.71, 95% CI: 2.29-3.20) had a
shorter OS (Table 3). 
Overall survival from complete remission with 
or without hematologic recovery
The 5-year OS rates from CR/CRi were 48.5%, 35.5%
and 11.4% in NotAdvMK–, AdvMK– and MK+ patients,
respectively (Figure 2B). The estimated hazard ratios com-
paring AdvMK– and MK+ patients to NotAdvMK– patients
were 1.50 and 2.87, respectively (Table 4). Comparing
MK+ to MK– (NotAdvMK– or AdvMK–) and AdvMK–
patients, the estimates of the hazard ratio were 2.73 (95%
CI: 2.17-3.45) and 1.91 (95% CI: 1.42-2.57), respectively.
In a multivariate Cox model, in comparison to
NotAdvMK–, AdvMK– (HR 1.52, 95% CI: 1.23-1.88) and
MK+ (HR 2.95, 95% CI: 2.32-3.74) were associated with
shorter OS from CR/CRi (Table 4). In a sensitivity analy-
sis, we modified the multivariate model by additionally
stratifying it by donor availability. The results of this
analysis were similar to those of the main analysis
(HR=1.59, 95% CI: 1.28-1.98 for AdvMK– versus
NotAdvMK– and HR=3.00, 95% CI: 2.35-3.82, for MK+
versus NotAdvMK–).
No impact of the type of anthracycline on outcomes 
in patients with a monosomal karyotype
Response data were available for 91 out of 93 MK+
patients from the AML-10 trial. CR/CRi was reached after
induction by 18 out of 32 patients in the daunorubicin arm
(56%), 14 out of 28 patients (50%) in the mitoxantrone
arm and 13 out of 31 (42%) patients in the idarubicin arm
(P=0.54). The 5-year OS rates were 13.0% (95% CI: 4.1-
27.1%) in daunorubicin patients, 6.7% (95% CI: 1.2-
19.2%) in mitoxantrone patients, and 11.7% (95% CI: 3.1-
26.6%) in idarubicin patients (Figure 2C). The 5-year OS
rates from CR/CRi were 17.6% (95% CI: 4.3-38.3%) in
daunorubicin patients, 11.5% (95% CI: 0.9-37.5%) in
idarubicin patients and 14.3% (95% CI: 2.3-36.6%) in
mitoxantrone patients (logrank P=0.53). 
No benefit of high-dose cytarabine in patients with
monosomal karyotype
Response data after induction were available for 93 out
of 95 MK+ and 978 out of 984 MK– patients from the AML-
12 trial. MK (present vs. absent) was of predictive impor-
tance for the effect of high-dose cytarabine on the proba-
bility of reaching CR/CRi after induction (interaction test
P-value: 0.01). MK– patients randomized to the high-dose
cytarabine arm were more likely to reach CR/CRi com-
F. Baron et al.
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Table 1. Patients’ characteristics.
Study                                               NotAdvMK-        AdvMK-          MK+
N. of patients                                                 1,584                    218                   188
MRC cytogenetic risk group, 
N. of patients (%)                                                                                                 
Adverse                                                             0                  218 (100)         179 (5)
Intermediate                                          1583 (100)                0                  9 (95)
Missing                                                             1                         0                       0
Trial                                                                                                                           
AML-10                                                            691                     127                    93
Daunorubicin, n. of patients (%)     221 (32.0)          29 (22.8)        32 (34.4)
Idarubicin, n. of patients (%)           226 (32.7)          56 (44.1)        31 (33.3)
Mitoxantrone, n. of patients (%)   244 (35.3)         42 (33.1)        30 (32.3)
AML-12                                                            893                      91                     95
SDAC, n. of patients (%)                  466 (52.2)         42 (46.2)        47 (49.5)
HiDAC, n. of patients (%)                 427 (47.8)         49 (53.8)        48 (50.5)
Male / Female, n.                                       792 / 790            107 / 111          109 / 79
Age (years), n. of patients (%)                                                                          
15-25                                                           155 (10)             28 (13)            15 (8)
26-45                                                           663 (42)             90 (41)           71 (38)
46-60                                                           766 (48)            100 (46)         102 (54)
WHO performance status, n. (%)                                                                     
0                                                                   679 (43)             84 (39)           62 (33)
1                                                                   672 (42)            104 (48)         100 (53)
2-4                                                               226 (14)             30 (14)           26 (14)
Missing                                                          7 (0)                                                
WBC x109/L at diagnosis, n. of patients (%)
< 25                                                            892 (56)            147 (67)         140 (75)
25-99.9                                                        496 (31)             51 (23)           38 (20)
≥100                                                            195 (12)              20 (9)             10 (5)
Missing                                                          1 (0)                  0 (0)               0 (0)
N. of  patients with CR/CRi                         1194                    137                    92
after induction 
Donor, n. among pts with CR/CRi (%)                                                              
No                                                             710 (59.5)          5 (54.7)         55 (59.8)
Yes                                                            412 (34.5)         58 (42.3)        35 (38.0)
Missing                                                     72 (6.0)            4 (2.9)            2 (2.2) 
NotAdvMK–: not adverse cytogenetic excluding a monosomal karyotype; AdvMK–:
adverse cytogenetic excluding a monosomal karyotype; MK+: monosomal karyotype;
SDAC, standard-dose cytarabine; HiDAC: high-dose cytarabine; WHO: World Health
Organization; WBC: white blood cell count; CR: complete remission; CRi, complete
remission with incomplete hematologic recovery.
pared to those randomized to the standard-dose cytarabine
arm (OR=1.51, 95% CI: 1.12-2.04; CR/CRi rate 80% vs.
73%, respectively). Among MK+ patients, 19 (1 without
hematologic recovery and 2 with missing hematologic
recovery data) out of 46 patients from the high-dose
cytarabine arm and 28 (5 without hematologic recovery
and 1 with missing hematologic recovery data) out of 47
patients in the standard-dose cytarabine arm reached
CR/CRi. In other words, in MK+ patients the trend was
even in a different direction (OR=0.48, 95% CI: 0.21-1.09;
CR/CRi rate 41% in the high-dose cytarabine arm vs. 60%
in the standard-dose cytarabine arm, P=0.080). Excluding
six patients without hematologic recovery, the CR rate
was 39% in the high-dose cytarabine arm versus 49% in
the standard-dose cytarabine arm. Furthermore, among 38
patients with reported CR with a full hematologic recovery
after induction, six (including 2 high-dose cytarabine and 4
standard-dose cytarabine patients) were reported not to
have had a full hematologic recovery after consolidation.
Interestingly, no benefit of high-dose cytarabine on OS
was observed in the subgroup of MK+ patients (HR=1.03,
95% CI: 0.68-1.57; P=0.88) (Figure 2D). The estimate of
the hazard ratio for OS after CR/CRi among MK+ patients
was 0.82 (95% CI: 0.44-1.53; P=0.53).
MK in EORTC/GIMEMA AML-10&12
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Figure 1. Flow chart of the patients included in the current analyses. MK: monosomal karyotype (MK-: without MK; MK+: with MK); OS: overall survival; CR/Cri: com-
plete remission/complete remission with incomplete blood count recovery; Allo-HSCT: allogeneic hematopoietic stem cell transplantation; Auto-HSCT: autologous
hematopoietic stem cell transplantation.
Having an HLA-identical related donor improved 
overall survival from complete remission in patients
with a monosomal karyotype
A total of 92 MK+ patients achieved a CR/CRi on study.
Among them, 35 patients had and 55 did not have an
HLA-identical related donor (information was missing for
2 patients). Among those with an HLA related donor, 25
patients (71%) received an allogeneic HSCT, including 20
(57%) who were transplanted in first CR/CRi (Figure 1). In
addition, 23 patients (including 22 without an HLA-
matched related donor) underwent autologous HSCT in
first CR/CRi.. The median time between CR/CRi and
HSCT in first CR/CRi was 91 days for patients who
received an autologous transplant (range, 42-167), 76 days
for patients who received an allogeneic HSCT (range, 46-
171), 91 days for patients without a donor (range: 42.0 -
171.0) and 71 days for patients with a donor (range, 46.0 -
148.0). OS from CR/CRi was longer in patients with a
donor than in those without, such that the 5-year OS rates
following CR/CRi were 24.1% (95% CI: 11.4-39.3%) and
3.8% (95% CI: 0.7-11.5%), respectively (HR=0.59, 95%
CI: 0.37-0.95) (Figure 3A).
Given the clinical importance of the observations
described just above, we performed several sensitivity
analyses to assess the impact of allogeneic HSCT on out-
comes among MK+ patients. The exclusion of patients
with a CRi had little impact on the estimated hazard ratio
(HR=0.60, 95% CI: 0.37-0.98). The advantage of having an
HLA-identical related donor remained present (HR=0.61,
95% CI: 0.38-0.99) after adjusting for patient’s age (< or ≥
45 years old).
Furthermore, the size of the estimated treatment effect
confirmed the benefit of allogeneic HSCT when the post-
transplant survival of patients who received an allogeneic
graft was compared to that of patients who received an
autologous graft (HR=0.54, 95% CI: 0.26-1.12) (Figure 3B).
Second, in a Cox model including allogeneic HSCT (mod-
eled as a time-varying covariate) and age, and stratified by
protocol, allogeneic HSCT was associated with a longer
survival from CR/CRi (HR=0.61, 95% CI: 0.36-1.02).
Discussion
As demonstrated in this study, several other studies
have established that the presence of a MK is associated
with a particularly poor outcome in younger AML
patients.8,15-17 However, the number of studies regarding
the best remission-induction regimens for MK+ AML
patients as well as the impact of allogeneic HSCT on the
outcomes of such patients have been the focus of only a
few studies.16,18 In order to investigate these important
issues, we used the data concerning the MK+ patients
included in the EORTC/GIMEMA AML-10 and AML-12
phase III multicenter trials. Several observations were
made.
First, our study confirms the poor prognosis associated
with MK+ in younger AML patients. Specifically, MK+ was
associated with a lower probability of achieving a
CR/CRi, a shorter OS and a shorter OS from CR/CRi,
whether taking other prognostic factors into account or
not. This is in concordance with prior observations that
the CR/CRi rate for adult MK+ patients ranged from 14-
43% and the OS rate from 9-18%.8,15-17
In addition, we investigated whether the type of anthra-
cycline given during remission induction affected the out-
comes of MK+ patients among patients included in the
AML-10 trial. Unfortunately, none of the assessed anthra-
cyclines was associated with better outcomes among MK+
patients. These findings are consistent with the results of
prior phase III trials showing that increasing the dose of
daunorubicin was beneficial mainly in patients with favor-
able or intermediate-risk cytogenetics.19,20
In the first analysis of the AML-12 trial, we observed
that induction with high-dose cytarabine increased the
proportion of patients achieving a CR/CRi and prolonged
OS in patients younger than 46 years of age.1 This benefit
was also observed in patients with adverse cytogenetic
abnormalities and/or FLT3-internal tandem duplication
(ITD) mutations, as well as in those with secondary AML.
Here we found no evidence of a benefit of high-dose
cytarabine in the subgroup of patients with a MK. There
was even a suggestion of a lower incidence of CR/CRi in
MK+ patients randomized to the high-dose cytarabine
arm. This finding could be explained by previous studies
showing that up to 80% of MK+ patients have a mutation
in the TP53 gene.21 Patients with TP53 mutation in their
tumor cells are resistant to high-dose cytarabine, as has
been demonstrated in patients with mantle cell lym-
phoma.22 Unfortunately, the TP53 gene mutation was not
evaluated in the present study.
Finally, we investigated whether patients with a donor
had an OS benefit in comparison to those without a
donor. As previously demonstrated by us and by other
groups of investigators, among MK– AML patients with
intermediate or unfavorable karyotype, the presence of a
F. Baron et al.
1172 haematologica | 2019; 104(6)
Table 2. Association between monosomal karyotype and Medical
Research Council adverse-risk group and achievement of complete
remission with or without hematologic recovery after induction.
Covariate                         OR of no CR/CRi       95% CI             P value 
Unadjusted analysis^
Cytogenetic group                                                                                      <0.001
NotAdvMK-                                        1                              
AdvMK-                                            1.80                   1.33 - 2.42
MK+                                                  3.09                   2.26 - 4.22
Multivariate analysis*
Cytogenetic group                                                                                      <0.001
NotAdvMK-                                        1
AdvMK-                                            1.91                   1.41 - 2.59
MK+                                                  3.34                   2.42 - 4.59
Age (years)                                                                                                    0.028
15-25                                                   1                              
26-45                                                1.35                   0.92 - 1.99
46-60                                                1.61                  1.10 - 2.36                    
WHO Performance Status at baseline                                                  <0.001
0                                                          1
1                                                        1.07                   0.85 - 1.34
2-4                                                    1.83                   1.35 - 2.48
WBC at diagnosis (x109/L)                                                                          0.001
<25                                                     1
≥ 25 and < 100                              1.21                   0.96 - 1.52
≥ 100                                                1.79                   1.31 - 2.46
OR: odds ratio; 95% CI: 95% confidence interval; NotAdvMK–: not adverse cytogenetic
excluding a monosomal karyotype; AdvMK–: adverse cytogenetic excluding a mono-
somal karyotype; MK+: monosomal karyotype; WHO: World Health Organization; WBC:
white blood cell count. ^Obtained with a logistic regression model including protocol
(AML-10 vs. AML-12) and cytogenetic group. *Obtained with a logistic regression
model including protocol and all covariates presented in the Table.
donor for an allogeneic HSCT prolonged OS.7,23
Interestingly, we made similar findings in patients with
MK+, suggesting a positive impact of allogeneic HSCT in
this population of patients with a generally poor outcome.
To our knowledge, our study is the first to investigate the
impact of allogeneic HSCT in MK+ patients using a donor
versus no donor comparison (which is considered as the
gold-standard technique to address this question when
donor availability is prospectively collected). These results
were further confirmed in a Cox model handling allogeneic
HSCT as a time-varying covariate and by comparing
patients who received an allogeneic transplant from an
HLA-matched related donor with those who received an
autologous transplant. The three approaches, which are
based on different assumptions, consistently indicated a
positive impact of allogeneic HSCT. Among 20 patients
who underwent allogeneic HSCT from an HLA-matched
related donor, two were still alive and in follow-up 10
years after reaching CR, indicating a curative potential of
the treatment. Importantly, our results are concordant with
prior results from Kayser et al., who observed that allo-
geneic HSCT prolonged OS in younger (18-60 years of age)
MK+ AML patients (using Mantel-Byar analysis)13, as well
as with a recent publication by Cornelissen et al., who
demonstrated better leukemia-free survival in younger
MK+ AML patients offered allogeneic HSCT (using a time-
dependent Cox analysis).18 This is also concordant with
previous studies showing that, although the prognosis of
MK+ patients remains worse than that of MK– patients after
transplantation, they have a 3-4 year OS probability rang-
ing from 25% to 34%.24,25 Interestingly, a study by the
Acute Leukemia Working Party of the European Society
for Blood and Marrow Transplantation observed relatively
comparable relapse incidence (HR=1.3, 95% CI: 0.7-2.6)
and OS (HR=0.9, 95% CI: 0.5-1.6) in MK+ patients given
grafts after reduced-intensity or myeloablative condition-
ing.25 This suggests that cure of MK+ patients after allogene-
ic HSCT might depend on immune-mediated graft-versus-
tumor effects rather than on the intensity of the condition-
ing regimen.26
In summary, this retrospective analysis of two large
prospective phase III trials confirmed the poor outcome of
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Figure 2. Impact of cytogenetic risk on overall survival and impact of randomization in patients with a monosomal karyotype. (A) Overall survival (OS) according
to cytogenetic risk group. (B) OS from complete remission/complete remission with incomplete blood count recovery according to cytogenetic risk group. (C) OS
according to randomized induction therapy in the AML-10 trial among patients with a monosomal karyotype. (D) OS according to randomized induction therapy in
the AML-12 trial among patients with a monosomal karyotype.  MK: monosomal karyotype; 95% CI: 95% confidence interval; NotAdvMK–: not adverse cytogenetics
excluding a monosomal karyotype; AdvMK–: adverse cytogenetics excluding a monosomal karyotype; MK+: monosomal karyotype.; DNR: daunorubicin; IDA: idaru-
bicin; MTX: Methotrexate.
A
C
B
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Table 3. Association between monosomal karyotype and Medical
Research Council adverse-risk group and overall survival.
Covariate                                    HR               95% CI                P value
Unadjusted analysis^
Cytogenetic group                                                                                      <0.001 
NotAdvMK-                                        1                                                             
AdvMK-                                            1.48                 1.26-1.74                          
MK+                                                  2.58                 2.19-3.04                          
Multivariate analysis*
Cytogenetic group                                                                                      <0.001
NotAdvMK-                                        1                                                             
AdvMK-                                            1.51                 1.28-1.77                          
MK+                                                  2.71                 2.29-3.20                          
Age (years)                                                                                                  <0.001
15-25                                                   1                                                             
26-45                                                1.05                 0.86-1.29                          
46-60                                                1.44                 1.18-1.75                          
WHO Performance Status at baseline                                                  <0.001
0                                                          1                                                             
1                                                        1.09                 0.97-1.23                          
2-4                                                    1.76                 1.50-2.07                          
WBC at diagnosis (x109/L)                                                                        <0.001
<25                                                     1                                                             
≥ 25 and < 100                              1.08                 0.95-1.22                          
≥ 100                                                1.42                 1.20-1.68                          
HR: hazard ratio; 95% CI: 95% confidence interval; NotAdvMK–: not adverse cytogenet-
ic excluding a monosomal karyotype; AdvMK–: adverse cytogenetic excluding a
monosomal karyotype; MK+: monosomal karyotype; WHO: World Health Organization;
WBC: white blood cell count. ^Obtained with a logistic regression model including
protocol (AML-10 vs. AML-12) and cytogenetic group. *Obtained with a logistic regres-
sion model including protocol and all covariates presented in the Table.
Table 4. Association between monosomal karyotype and Medical
Research Council adverse-risk group and overall survival from com-
plete remission with or without hematologic recovery.
Covariate                                 HR                  95% CI                P value
Unadjusted analysis^
Cytogenetic group                                                                                       <0.001
NotAdvMK-                                     1                                                                
AdvMK-                                         1.50                    1.22-1.85                          
MK+                                               2.87                    2.27-3.63                          
Multivariate analysis*
Cytogenetic group                                                                                       <0.001
NotAdvMK-                                     1                              -                                 
AdvMK-                                         1.52                    1.23-1.88                          
MK+                                               2.95                    2.32-3.74                          
Age (years)                                                                                                  <0.001
15-25                                               1                                                                
26-45                                             1.05                    0.82-1.35                          
46-60                                             1.46                    1.15-1.86                          
WHO Performance Status at baseline                                                    0.004
0                                                       1                                                                
1                                                     1.06                    0.92-1.23                          
2-4                                                 1.43                    1.16-1.78                          
WBC at diagnosis (x109/L)                                                                          0.069
<25                                                  1                                                                
≥ 25 and < 100                           1.00                    0.85-1.17                          
≥ 100                                            1.30                    1.03-1.64                          
HR: hazard ratio; 95% CI: 95% confidence interval; NotAdvMK–: not adverse cytogenet-
ic excluding a monosomal karyotype; AdvMK–: adverse cytogenetic excluding a
monosomal karyotype; MK+: monosomal karyotype; WHO: World Health Organization;
WBC: white blood cell count. ^Obtained with a logistic regression model including
protocol (AML-10 vs. AML-12) and cytogenetic group. *Obtained with a logistic regres-
sion model including protocol and all covariates presented in the Table.
Figure 3. Impact of allogeneic
hematopoietic stem cell trans-
plantation in patients with a
monosomal karyotype. (A) Overall
survival from complete remis-
sion/complete remission with
incomplete blood count recovery
according to donor availability
among patients with a monoso-
mal karyotype. (B) Overall survival
from hematopoietic stem cell
transplantation by type of trans-
plant among patients with a
monosomal karyotype. HR: hazard
ratio; 95% CI: 95% confidence
interval; CR/Cri: complete remis-
sion/complete remission with
incomplete blood count recovery;
HSCT: hematopoietic stem cell
transplantation; Auto-; autologous;
RD allo-: related donor allogeneic.
A
B
MK+ patients. We found no evidence that the outcome
was affected by the type of remission-induction
chemotherapy. Donor availability was associated with
prolonged survival among patients who reached a
CR/CRi, suggesting a positive effect of allogeneic HSCT in
this population of patients. These findings highlight the
need for further prospective studies assessing the best
strategy to bring MK+ patients to an allogeneic HSCT. In
addition, efforts should be made to prevent post-trans-
plant relapse and decrease transplant-related mortality in
MK+ AML patients. One possible strategy to do this could
be post-transplantation prophylactic administration of
hypomethylating agents, given their anti-leukemic activi-
ty in MK+ patients27 and their ability to prevent graft-ver-
sus-host disease.28
Funding
This publication was supported by a donation from the
"Fondation Contre le Cancer" from "Belgium" through the
EORTC Cancer Research Fund.
MK in EORTC/GIMEMA AML-10&12
haematologica | 2019; 104(6) 1175
References
1. Willemze R, Suciu S, Meloni G, et al. High-
dose cytarabine in induction treatment
improves the outcome of adult patients
younger than age 46 years with acute
myeloid leukemia: results of the EORTC-
GIMEMA AML-12 Trial. J Clin Oncol.
2014;32(3):219-228.
2. Mandelli F, Vignetti M, Suciu S, et al.
Daunorubicin versus mitoxantrone versus
idarubicin as induction and consolidation
chemotherapy for adults with acute
myeloid leukemia: the EORTC and
GIMEMA groups study AML-10. J Clin
Oncol. 2009;27(32):5397-5403.
3. Burnett AK, Russell NH, Hills RK, et al.
Optimization of chemotherapy for younger
patients with acute myeloid leukemia:
results of the Medical Research Council
AML15 trial. J Clin Oncol. 2013;31(27):3360-
3368.
4. Walter RB, Othus M, Burnett AK, et al.
Resistance prediction in AML: analysis of
4601 patients from MRC/NCRI,
HOVON/SAKK, SWOG and MD Anderson
Cancer Center. Leukemia. 2015;29(2):312-
320.
5. Dohner H, Estey EH, Amadori S, et al.
Diagnosis and management of acute
myeloid leukemia in adults: recommenda-
tions from an international expert panel, on
behalf of the European LeukemiaNet. Blood.
2010;115(3):453-474.
6. Grimwade D, Hills RK, Moorman AV, et al.
Refinement of cytogenetic classification in
acute myeloid leukemia: determination of
prognostic significance of rare recurring
chromosomal abnormalities among 5876
younger adult patients treated in the United
Kingdom Medical Research Council trials.
Blood. 2010;116(3):354-365.
7. Suciu S, Mandelli F, de Witte T, et al.
Allogeneic compared with autologous stem
cell transplantation in the treatment of
patients younger than 46 years with acute
myeloid leukemia (AML) in first complete
remission (CR1): an intention-to-treat analy-
sis of the EORTC/GIMEMAAML-10 trial.
Blood. 2003;102(4):1232-1240.
8. Breems DA, van Putten WL, De Greef GE, et
al. Monosomal karyotype in acute myeloid
leukemia: a better indicator of poor progno-
sis than a complex karyotype. J Clin Oncol.
2008;26(29):4791-4797.
9. Cornelissen JJ, Versluis J, Passweg JR, et al.
Comparative therapeutic value of post-
remission approaches in patients with acute
myeloid leukemia aged 40-60 years.
Leukemia. 2014;29(5):1041-1050.
10. Simons A, Shaffer LG, Hastings RJ.
Cytogenetic nomenclature: changes in the
ISCN 2013 compared to the 2009 edition.
Cytogenet Genome Res. 2013;141(1):1-6.
11. Kaplan EL, Meier P. Nonparametric estima-
tion from incomplete observations. J Am
Stat Assoc. 1958;53:457-481.
12. Greenwood M. The natural duration of can-
cer. Rep Public Health Med Subj 1926;33:1-
26.
13. Kalbfleisch JD, Prentice RL. The statistical
analysis of failure time data. John Wiley,
2002.
14. Cox DR. Regression models and life tables
(with discussion). J R Stat Soc Series B.
1972;34(2):187-220.
15. Medeiros BC, Othus M, Fang M, Roulston
D, Appelbaum FR. Prognostic impact of
monosomal karyotype in young adult and
elderly acute myeloid leukemia: the
Southwest Oncology Group (SWOG) expe-
rience. Blood. 2010;116(13):2224-2228.
16. Kayser S, Zucknick M, Dohner K, et al.
Monosomal karyotype in adult acute
myeloid leukemia: prognostic impact and
outcome after different treatment strategies.
Blood. 2012;119(2):551-558.
17. Yanada M, Kurosawa S, Yamaguchi T, et al.
Prognosis of acute myeloid leukemia harbor-
ing monosomal karyotype in patients treat-
ed with or without allogeneic hematopoietic
cell transplantation after achieving complete
remission. Haematologica. 2012;97(6):915-
918.
18. Cornelissen JJ, Breems D, van Putten WL, et
al. Comparative analysis of the value of allo-
geneic hematopoietic stem-cell transplanta-
tion in acute myeloid leukemia with mono-
somal karyotype versus other cytogenetic
risk categories. J Clin Oncol. 2012;30(17):
2140-2146.
19. Fernandez HF, Sun Z, Yao X, et al.
Anthracycline dose intensification in acute
myeloid leukemia. N Engl J Med.
2009;361(13):1249-1259.
20. Lowenberg B, Ossenkoppele GJ, van Putten
W, et al. High-dose daunorubicin in older
patients with acute myeloid leukemia. N
Engl J Med. 2009;361(13):1235-1248.
21. Rucker FG, Schlenk RF, Bullinger L, et al.
TP53 alterations in acute myeloid leukemia
with complex karyotype correlate with spe-
cific copy number alterations, monosomal
karyotype, and dismal outcome. Blood.
2012;119(9):2114-2121.
22. Delfau-Larue MH, Klapper W, Berger F, et al.
High-dose cytarabine does not overcome
the adverse prognostic value of CDKN2A
and TP53 deletions in mantle cell lym-
phoma. Blood. 2015;126(5):604-611.
23. Cornelissen JJ, van Putten WL, Verdonck LF,
et al. Results of a HOVON/SAKK donor ver-
sus no-donor analysis of myeloablative
HLA-identical sibling stem cell transplanta-
tion in first remission acute myeloid
leukemia in young and middle-aged adults:
benefits for whom? Blood. 2007;109(9):
3658-3666.
24. Fang M, Storer B, Estey E, et al. Outcome of
patients with acute myeloid leukemia with
monosomal karyotype who undergo
hematopoietic cell transplantation. Blood.
2011;118(6):1490-1494.
25. Poire X, Labopin M, Cornelissen JJ, et al.
Outcome of conditioning intensity in acute
myeloid leukemia with monosomal kary-
otype in patients over 45 year-old: a study
from the Acute Leukemia Working Party
(ALWP) of the European Group of Blood and
Marrow Transplantation (EBMT). Am J
Hematol. 2015;90(8):719-724.
26. Baron F, Labopin M, Niederwieser D, et al.
Impact of graft-versus-host disease after
reduced-intensity conditioning allogeneic
stem cell transplantation for acute myeloid
leukemia: a report from the Acute Leukemia
Working Party of the European group for
blood and marrow transplantation.
Leukemia. 2012;26(12):2462-2468.
27. Lubbert M, Suciu S, Hagemeijer A, et al.
Decitabine improves progression-free sur-
vival in older high-risk MDS patients with
multiple autosomal monosomies: results of
a subgroup analysis of the randomized
phase III study 06011 of the EORTC
Leukemia Cooperative Group and German
MDS Study Group. Ann Hematol.
2016;95(2):191-199.
28. Fransolet G, Ehx G, Somja J, et al.
Azacytidine mitigates experimental sclero-
dermic chronic graft-versus-host disease. J
Hematol Oncol. 2016;9(1):53.
